Citations

Clear

13 citation(s) found for "Mohan, Chandra".

Abstract B063: Succinate based metabolic reprogramming of CAR-macrophages for ovarian cancer immunotherapy
Hand, Alexis , Jaggarapu, Madhan Mohan Chandra Sekhar , Tonne, Jason M., Vile, Richard, Raja, Remya , Vile, Richard G. , Acharya, Abhinav P , Curtis, Marion

Mayo Clinic

Cancer Research | September 19, 2025 | Volume: 85 | Issue: 18_Supplement | Pages: B063-B063

10.1158/1538-7445.ovarian25-b063 Get It

Abstract Background: Despite the success of chimeric antigen receptor (CAR) T cell therapy in hematological malignancies, its efficacy in solid tumors remains limited. Macrophages, as key players in the innate immune response, offer unique advantages in the solid tumor context due to their ability to infiltrate tissues and phagocytose tumor cells. Preclinical studies have demonstrated that CAR-engineered macrophages (CAR-Ms) can penetrate solid tumors, initiate phagocytosis, and promote adaptive immunity. Early-phase clinical trials infusing CAR-Ms into patients have shown a favorable safety profile. However, within the immunosuppressive tumor microenvironment (TME), macrophages are often reprogrammed into tumor-promoting, M2-like tumor-associated macrophages (TAMs), which limit their therapeutic efficacy. Metabolic reprogramming is a critical driver of this polarization and TCA derived succinate has been shown to promote M1 phenotype in macrophages. In this study, we investigate whether succinate-loaded nanoparticles (PES NPs) can metabolically rewire CAR-Ms to maintain a pro-inflammatory (M1-like) phenotype and enhance antitumor activity in ovarian cancer (OC). Results: We synthesized polyethylene succinate (PES) nanoparticles (NPs) and analyzed their size, polydispersity, and zeta (ζ) potential using dynamic light scattering (DLS). The results showed a negative potential, indicative of stability, and suggested that succinate could be effectively encapsulated in nanoparticles. OC cells abundantly express mesothelin protein; therefore, mesothelin-targeting CARs were chosen to transfect mouse bone marrow-derived macrophages (BMDMs) or human monocyte-derived macrophages (HMDMs) to generate CAR-Ms. Our results showed that mouse and human CAR-Ms treated with PES NPs exhibited increased mitochondrial respiration and glycolysis, seen as elevated ECAR and OCR relative to vehicle control or cell-permeable dimethyl succinate ester (DMSA). Flow cytometry analysis revealed that PES treatment resulted in increased expression of markers of the classical M1 phenotype in both mouse and human CAR-Ms. The CAR-Ms also had elevated mRNA levels of proinflammatory cytokines like IL-6, TNFα, and IL1β, while anti-inflammatory cytokines like IL-10 remained low. Furthermore, IL-4-induced M2-like CAR-Ms could be reversed to an M1-like phenotype by PES NPs. Consistent with these results, PES NP-treated CAR-Ms exhibited increased phagocytic activity toward OC cells expressing mesothelin. Building on these in vitro results, the effect of PES NP-treated CAR-Ms on the reduction of tumor growth in OC tumor models will be further investigated. Conclusions: Our findings demonstrate that PES NPs effectively reprogram CAR-Ms to maintain a pro-inflammatory M1 phenotype. This reprogramming enhances their phagocytic activity and target cell killing in vitro. Collectively, these results support intracellular succinate delivery as a promising strategy to improve the efficacy of CAR-M-based therapies in OC. Citation Format: Remya Raja, Alexis Hand, Madhan Mohan Chandra Sekhar Jaggarapu, Jason Tonne, Richard Vile, Abhinav Acharya, Marion Curtis. Succinate based metabolic reprogramming of CAR-macrophages for ovarian cancer immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr B063.
Abstract 1845: 11,000-plex aptamer based proteomics of colorectal cancer stools for the discovery of novel disease biomarkers
Mohan, Chandra , Vanarsa, Kamala , Castillo, Jessica, Bresalier, Robert S. , Chia, Nicholas

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 1845-1845

10.1158/1538-7445.am2024-1845 Get It

Abstract Given the morbidity and mortality associated with colorectal cancer, novel biomarkers are clearly warranted, especially for early detection, particularly for advanced adenomas. An earlier 1317-plex aptamer-based proteomic screen of stool proteins revealed 92 proteins to be significantly elevated in CRC stool, with the most discriminatory proteins being MMP9, haptoglobin, myeloperoxidase, fibrinogen, and adiponectin (PMID: 34117903). Results from a recent 2000-plex proteomic screen of CRC stools are detailed below, while a 11,000-plex aptamer based proteomic screen is in progress. Comprehensive proteomic screening revealed 116 proteins to be differentially expressed in CRC stool compared to control stool, with 45 being elevated 2-fold or higher. 37 of these proteins were ELISA validated in 3 independent cohorts. Stool MMP-8, MMP-9, Hemoglobin, PGRP-S, Haptoglobin, Myeloperoxidase and Fibrinogen emerged as being most discriminatory for distinguishing CRC from healthy controls (AUC: 0.91-0.95), while Stool Fibrinogen, MMP-9, Hemoglobin, MMP-8, and PGRP-S best distinguished advanced adenoma from healthy control (HC) stool, with stool Fibrinogen topping the list with an ROC AUC value of 0.86, as detailed in Table 1. Functional pathway analysis revealed a significant over-representation of pathways related to anti-oxidant activity, integrin/receptor binding, cytokines, blood coagulation, and lipoprotein biosynthesis in patients with CRC compared to HC. Nuclear Factor IC (NFIC) and IKZF2 were identified as key regulators of the molecular cascades over-represented in CRC. Stool Fibrinogen, MMP-8, MMP-9, PGRP-S, Haptoglobin, and Myeloperoxidase emerge as promising biomarkers for distinguishing CRC/advanced adenomas/healthy stools, outperforming Hemoglobin. Thus, comprehensive proteomics and independent ELISA validation have uncovered novel stool biomarkers for identifying CRC and advanced adenomas, that warrant further head to head comparison against current diagnostic tests. Citation Format: Chandra Mohan, Kamala Vanarsa, Jessica Castillo, Robert Bresalier, Nicholas Chia. 11,000-plex aptamer based proteomics of colorectal cancer stools for the discovery of novel disease biomarkers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1845.
Inverse‐Vaccines for Rheumatoid Arthritis Re‐establish Metabolic and Immunological Homeostasis in Joint Tissues
Thumsi, Abhirami , Martínez, Diego , Swaminathan, Srivatsan J. , Esrafili, Arezoo , Suresh, Abhirami P. , Jaggarapu, Madhan Mohan Chandrasekhar, Lintecum, Kelly , Halim, Michelle, Mantri, Shivani, Sleiman, Yasmine, Appel, Nicole, Gu, Haiwei , Acharya, Abhinav P , Jaggarapu, Madhan Mohan Chandra Sekhar , Curtis, Marion , Zúñiga, Cristal

Mayo Clinic

Advanced Healthcare Materials | March 12, 2024 | Volume: 14 | Issue: 5 | Pages: No page available

10.1002/adhm.202303995 | PMID 38469995 Get It

Abstract Rheumatoid arthritis (RA) causes immunological and metabolic imbalances in tissue, exacerbating inflammation in affected joints. Changes in immunological and metabolic tissue homeostasis at different stages of RA are not well understood. Herein, the changes in the immunological and metabolic profiles in different stages in collagen induced arthritis (CIA), namely, early, intermediate, and late stage is examined. Moreover, the efficacy of the inverse‐vaccine, paKG(PFK15+bc2) microparticle, to restore tissue homeostasis at different stages is also investigated. Immunological analyses of inverse‐vaccine‐treated group revealed a significant decrease in the activation of pro‐inflammatory immune cells and remarkable increase in regulatory T‐cell populations in the intermediate and late stages compared to no treatment. Also, glycolysis in the spleen is normalized in the late stages of CIA in inverse‐vaccine‐treated mice, which is similar to no‐disease tissues. Metabolomics analyses revealed that metabolites UDP‐glucuronic acid and L‐Glutathione oxidized are significantly altered between treatment groups, and thus might provide new druggable targets for RA treatment. Flux metabolic modeling identified amino acid and carnitine pathways as the central pathways affected in arthritic tissue with CIA progression. Overall, this study shows that the inverse‐vaccines initiate early re‐establishment of homeostasis, which persists through the disease span.
A peptoid interleukin‐15 receptor antagonist suppresses inflammation and arthritis in mice
Cho, Kwang Bog , Shukla, Satya Prakash , Kannan, Maheshkumar, Amina, Sundus Jabeen, Chen, Yanping , Molligan, Jeremiah F., Mohan, Chandra , Udugamasooriya, D. Gomika , Guo, Bin , Udugamasooriya, D Gomika , Guo, Bin , Zhang, Haowen , Zhou, Shuang Ying , Chen, Yanping, Taneja, Veena

Mayo Clinic

Clinical & Translational Immunology | November 24, 2022 | Volume: 11 | Issue: 11 | Pages: No page available

10.1002/cti2.1432 | PMID 36439637 Get It

AbstractObjectiveTo discover a novel peptoid antagonist that targets the interleukin‐15 (IL‐15) receptor and to evaluate its therapeutic efficacy in the treatment of inflammation and arthritis.MethodsA new compound (IFRA3, interleukin‐15 receptor antagonist 3) was discovered using a unique on‐bead two‐colour combinatorial cell screening of a peptoid library. The interaction of IFRA3 with IL‐15 receptor was assessed by in vitro pull‐down and thermal shift assays. The efficacy of IFRA3 in treating inflammation and arthritis was evaluated in mouse models.ResultsIFRA3Q1 (a tetrameric derivative of IFRA3) inhibited the activity of IL‐15 and suppressed CTLL‐2 cell proliferation (which depends on IL‐15 activity). IFRA3Q1 exhibited strong in vivo anti‐inflammatory activity in carrageenan‐induced inflammation in mice. Furthermore, IFRA3Q1 inhibited collagen‐induced arthritis in DBA/1J mice.ConclusionBy binding to and inhibiting the function of IL‐15 receptor, IFRA3Q1 exhibited significant anti‐arthritis activity. Our findings suggest that IFRA3Q1 represents a new paradigm for arthritis therapy by targeting IL‐15 signalling.
Ultrasonic Percutaneous Tenotomy for Recalcitrant Lateral Elbow Tendinopathy: Clinical and Sonographic Results at 90 Months
Ang, Benjamin F.H., Mohan, P. Chandra, Png, Meng Ai , Howe, Tet Sen , Morrey, B.F. , Morrey, Bernard F, Mohan, P. Chandra, Allen, John Carson , Koh, Joyce Suang Bee , Lee, Brian P.

Mayo Clinic

The American Journal of Sports Medicine | May 9, 2021 | Volume: 49 | Issue: 7 | Pages: 1854-1860

10.1177/03635465211010158 | PMID 33956537 Get It

Background: In a study from our institution, ultrasonic percutaneous tenotomy of the brevis and the common extensor tendon for recalcitrant lateral elbow tendinopathy showed excellent safety profiles, high tolerability, efficiency, sustained pain relief, functional improvement, and sonographic evidence of tissue healing in 20 patients at 3 years’ follow-up. Purpose: To explore the long-term clinical and sonographic results of ultrasonic percutaneous tenotomy of the brevis and the common extensor tendon. Study Design: Case series; Level of evidence, 4. Methods: The same cohort of 20 patients was recalled after 7 years, and visual analog scale (VAS) for pain and Disabilities of the Arm, Shoulder and Hand (DASH) scores, need for secondary intervention, and overall satisfaction were assessed. They were also reassessed using ultrasound imaging of the brevis and the common extensor tendon to evaluate tendon hypervascularity, tendon thickness, and the progress or the recurrence of the hypoechoic scar tissue. Results: We successfully scored 19 patients and performed ultrasound on 16 patients with a median follow-up of 90 months (range, 86-102 months). There were no adverse outcomes and satisfaction remained at 100% (6 patients, satisfied; 13 patients, very satisfied). No patient developed a recurrence of symptoms and signs of lateral elbow tendinopathy, and therefore no secondary intervention was required. The improvement from baseline and early term scores was sustained ( P < .001 for all). At 90 months, there was a significant improvement in VAS scores and DASH–Compulsory scores compared with preprocedure scores and all follow-up times until 3 months. There was no difference in VAS scores and DASH–Compulsory scores at 90 months compared with 6 and 36 months. For DASH–Work scores, there was a significant improvement at 90 months compared with preprocedure scores, but there was no difference between DASH–Work scores at 90 months and scores at all other points of follow-up. At 90 months, hypervascularity remained resolved in 79% of patients, while all patients had reduced tendon swelling and sustained resolution or reduction of the hypoechoic lesion. Conclusion: At the long-term follow-up of 90 months, ultrasonic percutaneous tenotomy of the brevis and the common extensor tendon, previously shown to enhance recovery of lateral elbow tendinopathy, demonstrated good durability of pain relief and functional recovery that was previously achieved. This was accompanied by sustained sonographic tissue healing with no significant deterioration.
Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer
González-Guerrico, Anatilde M., Espinoza, Ingrid , Schroeder, Barbara, Park, Cheol Hong, KVP, Chandra Mohan, Khurana, Ashwani, Corominas-Faja, Bruna, Cuyàs, Elisabet , Alarcón, Tomás , Kleer, Celina G. , Menéndez, Javier A. , Lupu, Ruth , Menendez, Javier A , Cuyàs, Elisabet

Mayo Clinic

Oncotarget | May 19, 2016 | Volume: 7 | Issue: 44 | Pages: 71151-71168

10.18632/oncotarget.9463 | PMID 27223424 Get It

Ultrasonic Percutaneous Tenotomy for Recalcitrant Lateral Elbow Tendinopathy
Seng, Chusheng, Mohan, P. Chandra, Koh, Suang Bee, Howe, Tet Sen , Lim, Yee Gen , Morrey, B.F. , Morrey, Bernard F, Mohan, P. Chandra, Lee, Brian P.

Mayo Clinic

The American Journal of Sports Medicine | November 24, 2015 | Volume: 44 | Issue: 2 | Pages: 504-510

10.1177/0363546515612758 | PMID 26602153 Get It

Background: A previously published study found positive outcomes for a novel technique for ultrasound-guided percutaneous ultrasonic tenotomy, showing good tolerability, safety, and early efficacy within an office setting. Purpose: In this follow-up study, all 20 members of the original cohort were contacted after 3 years to explore the sustainability of symptomatic relief, functional improvement, and sonographic soft tissue response for percutaneous ultrasonic tenotomy. Study Design: Case series; Level of evidence, 4. Methods: All 20 subjects of the clinical trial that was performed from June to November 2011 were further assessed at 36 months after the procedure in terms of visual analog scale for pain, Disabilities of the Arm, Shoulder and Hand (DASH)–Compulsory/Work scores, need for adjunct procedures, and overall satisfaction. Importantly, all 20 were reassessed with ultrasound imaging at 36 months, and evidence of the common extensor tendon response was assessed in terms of tendon hypervascularity, tendon thickness, and the progress of the hypoechoic scar tissue. Results: A 100% clinical follow-up was achieved, inclusive of ultrasonographic assessment. None of the subjects required further treatment procedures, and 100% expressed satisfaction. Previous improvements in visual analog scale (current median ± SD, 0 ± 0.9; range, 0-3) and DASH-Work scores (current median, 0 ± 0) were sustained with conformity to a linear pattern on polynomial measures. There was further reduction in DASH-Compulsory scores to a median of 0 ± 0.644 (range, 0-2) with a significant decrease on repeated measures ( P = .008). Tendon hypervascularity was resolved in 94% of patients, and 100% had reduction in tendon thickness. Overall reduction in the hypoechoic scar tissue was observed in all subjects, with a 90% response achieved by 6 months. Between 6 and 36 months, further reduction in the scar was observed in around 60% of patients, with 20% of patients having complete resolution of the hypoechoic scar. Conclusion: Minimally invasive percutaneous ultrasonic tenotomy provided sustained pain relief and functional improvement for recalcitrant tennis elbow at 3-year follow-up. It is one of the few procedures to demonstrate positive sonographic evidence of tissue-healing response and is an attractive alternative to surgical intervention for definitive treatment of recalcitrant elbow tendinopathy.
Abstract 2713: Small-molecule FASN inhibitors promote growth inhibition growth and apoptosis of breast cancer
Lupu, Ruth , Guerrico, Anatilde González, Khurana, Ashwani, Heuer, Timothy S., Kemble, George, KVP, Chandra Mohan

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 2713-2713

10.1158/1538-7445.am2014-2713 Get It

Abstract Increased de novo lipogenesis due to enhanced expression of several lipogenic enzymes has been found in many types of human cancers. Fatty acid synthase (FASN), the key enzyme in the de novo lipogenesis pathway, is one of the most commonly over-expressed lipogenic enzymes. Studies in the past decade have recognized FASN overexpression as a molecular marker for poor prognosis and malignant phenotype of many cancers. Tumor-associated FASN, by conferring growth and survival advantages rather than functioning as an anabolic energy-storage pathway, has also been suggested to play an active part in the development, maintenance, and metastatic progression of human cancers. More recently, FASN has been implicated in contributing to cellular resistance to several anticancer treatments. A variety of agents have been developed to target lipogenic enzymes and the key regulators involved in lipid metabolism in cancer cell for therapeutic purposes. The development of several FASN inhibitors has been reported from both academic labs and industries. When used in in vitro, xenograft and genetically induced mouse model studies, these inhibitors have supported FASN as an excellent target. A new generation of FASN inhibitors was developed at 3-V Biosciences that are highly specific, reversible inhibitors of FASN. One compound in this series, TVB-2640, is orally bioavailable and has progressed into Phase 1 clinical studies. The effect of two anti-FASN drugs in this series, TVB-3150 and TVB-3199 were tested for their effect on breast cancer cells. We demonstrated that the EC50 is between 9-50 nM, depending on the drug and the tested cell line. We then demonstrated that the drugs inhibited the anchorage-dependent and -independent growth of FASN expressing cells in a dose dependent manner. The apparent mechanism by which the FASN inhibitors promote inhibition of growth is by inducing apoptotic cell death in a time- and dose-dependent manner that involves regulation of apoptotic and pro-apoptotic proteins. Furthermore, the combination of the anti-FASN drugs with small molecule inhibitors of the antiapoptotic proteins Bcl-2 and Bcl-xL significantly increased the apoptotic effect in a synergistic manner compared to either of the synthetic inhibitors alone. In vivo studies demonstrate tumor growth inhibition without toxicity. Clinical development of a first-in-class, orally active, potent, and reversible FASN inhibitor as a novel cancer therapeutic is ongoing. Citation Format: Ruth Lupu, Anatilde Gonzalez Guerrico, Ashwani Khurana, Timothy Heuer, George Kemble, Chandra Mohan KVP. Small-molecule FASN inhibitors promote growth inhibition growth and apoptosis of breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2713. doi:10.1158/1538-7445.AM2014-2713
Abstract 1737: Pharmacological inhibition of fatty acid synthase regulates BH3-only proteins and sensitizes breast cancer cells to a small molecule Bcl-2/Bcl-xL inhibitor to induce apoptosis.
Venkatapoorna, Chandra Mohan Kurapaty, Espinoza, Ingrid, Kaufmann, Scott H. , Lupu, Ruth , Espinoza, Ingrid , Kaufmann, Scott H

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 1737-1737

10.1158/1538-7445.am2013-1737 Get It

Abstract Fatty acid synthase (FASN), the key enzyme in de novo lipogenesis, is significantly upregulated and activated in many carcinomas, including breast cancer. Pharmacological inhibition of FASN induces apoptosis of FASN expressing cancer cells. However, the mechanism is still unclear. Inhibition of FASN in breast cancer cells induces a dose dependent increase in apoptotic cell death with a concomitant upregulation of the pro-apoptotic BH3-only proteins Noxa, Bim and Puma (mRNA and protein). Blockage of the BH3-only protein expression using specific small interfering ribonucleic acid (siRNA), significantly diminishes the apoptotic effect induced by the inhibition of FASN. Moreover, addition of palmitate, the end product of FASN, protects the cells from the proapoptotic effects of FASN inhibition by suppressing expression of Noxa, Bim and Puma. These data indicate that Noxa, Bim and Puma are essential for the apoptotic effect induced by the inhibition of FASN. Combination therapeutic regimens have received growing attention for the possibility of higher efficacy with reduced toxicity. Thus, we investigated the combinatorial effect of pharmacological inhibition of FASN and Bcl-2/Bcl-xL. While a small molecule Bcl-2/Bcl-xL inhibitor alone did not induce apoptosis, co-treatment of the small molecule Bcl-2/Bcl-xL inhibitor with a synthetic FASN inhibitor significantly surpassed the apoptotic effect of the synthetic FASN inhibitor alone. Accordingly, combined treatment of a FASN inhibitors and Bcl-2/Bcl-xL antagonists represents a new rational combination that merits further consideration in FASN overexpressing tumors. Citation Format: Chandra Mohan Kurapaty Venkatapoorna, Ingrid Espinoza, Scott H Kaufmann, Ruth Lupu. Pharmacological inhibition of fatty acid synthase regulates BH3-only proteins and sensitizes breast cancer cells to a small molecule Bcl-2/Bcl-xL inhibitor to induce apoptosis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1737. doi:10.1158/1538-7445.AM2013-1737 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.